This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cipriano, S. C. Articles by Matzuk, M. M. Search for Related Content PubMed PubMed Citation Articles by Cipriano, S. C. Articles by Matzuk, M. M.

Follistatin Is a Modulator of Gonadal Tumor Progression and the Activin-Induced Wasting Syndrome in Inhibin-Deficient Mice¹

Departments of Pathology (S.C.C., L.C., T.R.K., M.M.M.), Molecular and Cellular Biology (T.R.K., M.M.M.), and Molecular and Human Genetics (M.M.M.), Baylor College of Medicine, Houston, Texas 77030

Address all correspondence and requests for reprints to: Martin M. Matzuk, M.D., Ph.D., Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030. E-mail: mmatzuk{at}bcm.tmc.edu

Inhibins and activins are dimeric proteins belonging to the transforming growth factor-ß superfamily. Follistatin is an activin-binding protein that antagonizes the function of activin via binding to its ß-subunits. Previously, we demonstrated that mice deficient in inhibin develop ovarian and testicular sex cord-stromal tumors of granulosa and Sertoli cell origin, with 100% penetrance as early as 4 weeks of age. Overproduction of activins in the serum directly causes a cachexia-like wasting syndrome that results in lethality of these mice at an early stage after the onset of the tumors. In an independent set of studies, overexpression of mouse follistatin using the mouse metallothionein I promoter in transgenic mice led to gonadal defects and eventual infertility, primarily due to local effects of follistatin in these tissues. Activin has a positive growth effect on gonadal tumor cells in culture and directly causes the cancer cachexia-like syndrome in inhibin-deficient mice via interaction with activin receptor type IIA in livers and stomachs. We therefore hypothesized that an activin antagonist such as follistatin can act as a physiological modifier, either locally or via the serum, to block the activin-mediated cancer cachexia-like syndrome in inhibin-deficient mice and/or slow the progression of gonadal cancers in these mice. To test this hypothesis, we generated mice that are homozygous mutant for the inhibin null allele (i.e. inha^m1/inha^m1) and carry the mouse metallothionein I follistatin (MT-FS) transgene. Our results show that gonadal tumors that are histologically similar in most, but not all, cases to the tumors in inhibin-deficient mice develop in these inha^m1/inha^m1, MT-FS⁺ mice. However, inha^m1/inha^m1, MT-FS⁺ mice exhibit a less severe wasting syndrome, lower serum activin levels, and a statistically significant prolonged survival in a number of cases compared with mice deficient in inhibin alone. Thus, follistatin can act as a modulator of tumor growth and the activin-induced cancer cachexia-like syndrome in inhibin-deficient mice.

This article has been cited by other articles:

				Q. Li, J. M. Graff, A. E. O'Connor, K. L. Loveland, and M. M. Matzuk SMAD3 Regulates Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2007; 21(10): 2472 - 2486. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				C. Andreu-Vieyra, R. Chen, and M. M. Matzuk Effects of Granulosa Cell-Specific Deletion of Rb in Inha-{alpha} Null Female Mice Endocrinology, August 1, 2007; 148(8): 3837 - 3849. [Abstract] [Full Text] [PDF]

				C. J. Guigon and S. Magre Contribution of Germ Cells to the Differentiation and Maturation of the Ovary: Insights from Models of Germ Cell Depletion Biol Reprod, March 1, 2006; 74(3): 450 - 458. [Abstract] [Full Text] [PDF]

				K. H. Burns, J. E. Agno, P. Sicinski, and M. M. Matzuk Cyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin {alpha} Knockout Mice Mol. Endocrinol., October 1, 2003; 17(10): 2053 - 2069. [Abstract] [Full Text] [PDF]

				P. J. Fuller, E. T. Zumpe, S. Chu, P. Mamers, and H. G. Burger Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1395 - 1401. [Abstract] [Full Text] [PDF]

				J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				S. C. Cipriano, L. Chen, K. H. Burns, A. Koff, and M. M. Matzuk Inhibin and p27 Interact to Regulate Gonadal Tumorigenesis Mol. Endocrinol., June 1, 2001; 15(6): 985 - 996. [Abstract] [Full Text] [PDF]